By downregulating the combined molecular targets, such as c-MET, STAT3, and AKT and their phosphorylated forms, the activation and overexpression of cancer stem cell-like cells is suppressed along with drug resistance signaling, hence improving the overall survival of the patients. This evidence concerns the gene MET and cancer.